News – Page 1155 – Endpoints News

Ex-Allergan prez Ingram forges $1B deal to sell Alzheimer’s biotech to Brent Saunders and the new crew at Allergan

9 years ago

Biogen vet Adam Koppel is raising cash for a new life sciences fund at Bain Capital

9 years ago

Fate raises $57M; Biogen vet named CSO at Scholar Rock

9 years ago

Thinking bigger, Arch Venture closes in on $550M-plus biotech fund

9 years ago

Eau de poop: Bill Gates tests a new way to sweeten the world’s worst odors

9 years ago

Booming rare disease player Shire adding a trendy new R&D hub in Kendall Square for 1,000-plus

9 years ago

It’s a tie: Sanofi and Novo come in neck-and-neck at the FDA with two new diabetes combo OKs

9 years ago

After a painful stumble, AstraZeneca gets top checkpoint cancer program back on track

9 years ago

Aduro gets back on track with CRS-207 after FDA lifts partial clinical hold

9 years ago

Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug

9 years ago

Chiesi picks a pipeline fight with Novartis, going head-to-head on a big new target for asthma

9 years ago

Acorda writes off another R&D program as Ampyra flops in stroke study

9 years ago

Novartis swoops in to bag Selexys and its sickle cell drug in $665M deal

9 years ago

Goodbye, San Francisco. Stanford spinout heads to Houston after bagging a $20M CPRIT grant

9 years ago

Dinner and a biotech chat: Billionaire Patrick Soon-Shiong talks 'innovation' with President-elect Trump

9 years ago

MD Anderson to biotech billionaire Soon-Shiong: Get your own slogan. ‘Moon Shots’ belongs to us

9 years ago

Donald Trump is starting to win over biopharma

9 years ago

Motif strikes a deal needed to trigger Nasdaq IPO; OncoGenex cuts more staffers to conserve cash

9 years ago

Florida's decade-old incentive program to lure research institutions is going belly up

9 years ago

Gilead punts hep B drug as GlobeImmune joins the (dead quiet) ranks of zombie biotechs

9 years ago

Spectrum floats new PhIII idea after FDA slaps down failed bladder cancer drug

9 years ago

Gilead needs to stop waiting and start buying; Let's embrace China as a new biopharma power

9 years ago

J&J takes one of its top blockbuster prospects to the FDA, in search of a big approval

9 years ago

Fledgling biotech Syntimmune looks to take flight in the clinic with a new CEO and a slightly less virtual business ...

9 years ago

First page Previous page 1152 1153 115411551156 1157 1158 Next page Last page